Showing results (41-50 of 114) with videos related to
Sort By:
Pageof 12
Breast (Edinburgh, Scotland)|August 14, 2016
Validated biomarkers: The key to precision treatment in patients with breast cancerMichael J Duffy, Norma O'Donovan, Enda McDermott, et al.Nutrition and Cancer|December 10, 2022
Vitamin D Supplementation: Does It Have a Preventative or Therapeutic Role in Cancer?Michael J Duffy, Maeve Mullooly, Kathleen Bennett, et al.Cancer Treatment Reviews|February 1, 2021
MYC as a target for cancer treatmentMichael J Duffy, Shane O'Grady, Minhong Tang, et al.Breast Cancer Research and Treatment|September 21, 2019
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cellsNaoise C Synnott, David O'Connell, John Crown, et al.Advances in Clinical Chemistry|September 29, 2015
Biomarkers in Breast Cancer: Where Are We and Where Are We Going?Michael J Duffy, Siun Walsh, Enda W McDermott, et al.Expert Opinion on Therapeutic Targets|August 3, 2014
cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?Patricia B Gaule, John Crown, Norma O'Donovan, et al.Cancer Biology & Therapy|April 27, 2016
The ADAMs family of proteases as targets for the treatment of cancerMaeve Mullooly, Patricia M McGowan, John Crown, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Role of ADAMs in cancer formation and progressionMichael J Duffy, Eadaoin McKiernan, Norma O'Donovan, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|May 2, 2009
The role of ADAMs in disease pathophysiologyMichael J Duffy, Eadaoin McKiernan, Norma O'Donovan, et al.Seminars in Cancer Biology|August 4, 2020
Targeting p53 for the treatment of cancerMichael J Duffy, Naoise C Synnott, Shane O'Grady, et al.Pageof 12